vs
Side-by-side financial comparison of Magnera Corp (MAGN) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Magnera Corp is the larger business by last-quarter revenue ($792.0M vs $493.8M, roughly 1.6× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -4.3%, a 11.1% gap on every dollar of revenue. On growth, Magnera Corp posted the faster year-over-year revenue change (12.8% vs -1.7%). Over the past eight quarters, Magnera Corp's revenue compounded faster (54.9% CAGR vs -0.1%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
MAGN vs MD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $493.8M |
| Net Profit | $-34.0M | $33.7M |
| Gross Margin | 12.2% | — |
| Operating Margin | 1.8% | 9.9% |
| Net Margin | -4.3% | 6.8% |
| Revenue YoY | 12.8% | -1.7% |
| Net Profit YoY | 43.3% | 10.5% |
| EPS (diluted) | $-0.95 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $792.0M | $493.8M | ||
| Q3 25 | — | $492.9M | ||
| Q2 25 | $839.0M | $468.8M | ||
| Q1 25 | $824.0M | $458.4M | ||
| Q4 24 | $702.0M | $502.4M | ||
| Q3 24 | $332.1M | $511.2M | ||
| Q2 24 | $556.0M | $504.3M | ||
| Q1 24 | $558.0M | $495.1M |
| Q4 25 | $-34.0M | $33.7M | ||
| Q3 25 | — | $71.7M | ||
| Q2 25 | $-18.0M | $39.3M | ||
| Q1 25 | $-41.0M | $20.7M | ||
| Q4 24 | $-60.0M | $30.5M | ||
| Q3 24 | $-15.2M | $19.4M | ||
| Q2 24 | $19.0M | $-153.0M | ||
| Q1 24 | $14.0M | $4.0M |
| Q4 25 | 12.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 6.2% | — |
| Q4 25 | 1.8% | 9.9% | ||
| Q3 25 | — | 13.8% | ||
| Q2 25 | 1.5% | 12.8% | ||
| Q1 25 | 0.5% | 7.0% | ||
| Q4 24 | -3.1% | 7.8% | ||
| Q3 24 | 0.9% | 6.6% | ||
| Q2 24 | 3.1% | -31.3% | ||
| Q1 24 | 3.8% | 3.2% |
| Q4 25 | -4.3% | 6.8% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | -2.1% | 8.4% | ||
| Q1 25 | -5.0% | 4.5% | ||
| Q4 24 | -8.5% | 6.1% | ||
| Q3 24 | -4.6% | 3.8% | ||
| Q2 24 | 3.4% | -30.3% | ||
| Q1 24 | 2.5% | 0.8% |
| Q4 25 | $-0.95 | $0.40 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | $-0.51 | $0.46 | ||
| Q1 25 | $-1.15 | $0.24 | ||
| Q4 24 | $-1.69 | $0.37 | ||
| Q3 24 | $-0.33 | $0.23 | ||
| Q2 24 | $0.60 | $-1.84 | ||
| Q1 24 | $0.44 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.0M | $375.2M |
| Total DebtLower is stronger | $1.9B | $570.5M |
| Stockholders' EquityBook value | $1.0B | $865.9M |
| Total Assets | $3.9B | $2.2B |
| Debt / EquityLower = less leverage | 1.86× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $264.0M | $375.2M | ||
| Q3 25 | — | $340.1M | ||
| Q2 25 | $276.0M | $224.7M | ||
| Q1 25 | $282.0M | $99.0M | ||
| Q4 24 | $215.0M | $229.9M | ||
| Q3 24 | $230.0M | $103.8M | ||
| Q2 24 | $33.9M | $19.4M | ||
| Q1 24 | $30.2M | $8.0M |
| Q4 25 | $1.9B | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | $2.0B | $583.9M | ||
| Q1 25 | $2.0B | $590.5M | ||
| Q4 24 | $2.0B | $597.1M | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $877.4M | — | ||
| Q1 24 | $884.7M | — |
| Q4 25 | $1.0B | $865.9M | ||
| Q3 25 | — | $890.7M | ||
| Q2 25 | $1.1B | $833.8M | ||
| Q1 25 | $1.1B | $789.2M | ||
| Q4 24 | $1.1B | $764.9M | ||
| Q3 24 | $2.1B | $732.5M | ||
| Q2 24 | $2.4B | $706.5M | ||
| Q1 24 | $2.4B | $856.2M |
| Q4 25 | $3.9B | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $4.1B | $2.1B | ||
| Q1 25 | $4.1B | $2.0B | ||
| Q4 24 | $4.0B | $2.2B | ||
| Q3 24 | $2.8B | $2.1B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | 1.86× | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | 1.77× | 0.70× | ||
| Q1 25 | 1.83× | 0.75× | ||
| Q4 24 | 1.80× | 0.78× | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $114.1M |
| Free Cash FlowOCF − Capex | $-13.0M | — |
| FCF MarginFCF / Revenue | -1.6% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $114.1M | ||
| Q3 25 | — | $137.3M | ||
| Q2 25 | $0 | $137.2M | ||
| Q1 25 | $65.0M | $-117.5M | ||
| Q4 24 | $-58.0M | $133.0M | ||
| Q3 24 | $12.2M | $91.8M | ||
| Q2 24 | $38.0M | $107.0M | ||
| Q1 24 | $20.0M | $-125.2M |
| Q4 25 | $-13.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $-74.0M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $23.0M | — | ||
| Q1 24 | $12.5M | — |
| Q4 25 | -1.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | -10.5% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | 2.00× | — | ||
| Q1 24 | 1.43× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
